Apolipoprotein E (ApoE) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Apolipoprotein E (ApoE) - Pipeline Review, H1 2016

Apolipoprotein E (ApoE) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Apolipoprotein E (ApoE) - Pipeline Review, H1 2016
Published Jun 22, 2016
45 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Apolipoprotein E (ApoE) - Pipeline Review, H1 2016, provides in depth analysis on Apolipoprotein E (ApoE) targeted pipeline therapeutics.

The report provides comprehensive information on the Apolipoprotein E (ApoE) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Apolipoprotein E (ApoE) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Apolipoprotein E (ApoE)
- The report reviews Apolipoprotein E (ApoE) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Apolipoprotein E (ApoE) targeted therapeutics and enlists all their major and minor projects
- The report assesses Apolipoprotein E (ApoE) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Apolipoprotein E (ApoE) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Apolipoprotein E (ApoE)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most pro

  
Source:
Document ID
GMDHC0067TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables41
  List of Figures41
Introduction51
  Global Markets Direct Report Coverage51
Apolipoprotein E (ApoE) Overview61
Therapeutics Development73
  Apolipoprotein E (ApoE) Products under Development by Stage of Development71
  Apolipoprotein E (ApoE) Products under Development by Therapy Area81
  Apolipoprotein E (ApoE) Products under Development by Indication91
Apolipoprotein E (ApoE) Pipeline Products Glance102
  Late Stage Products101
  Early Stage Products111
Apolipoprotein E (ApoE) Products under Development by Companies122
Apolipoprotein E (ApoE) Products under Development by Universities/Institutes142
Apolipoprotein E (ApoE) Therapeutics Assessment167
  Assessment by Monotherapy/Combination Products161
  Assessment by Mechanism of Action172
  Assessment by Route of Administration192
  Assessment by Molecule Type212
Apolipoprotein E (ApoE) Companies Involved in Therapeutics Development232
  LipimetiX Development, Inc.231
  ReXceptor Inc.241
Apolipoprotein E (ApoE) Drug Profiles259
  AEM-28 Drug Profile253
  AEM-2802 Drug Profile281
  AEM-2814 Drug Profile291
  bexarotene Drug Profile301
  Monoclonal Antibodies to Target ApoE for Alzheimer's Disease Drug Profile311
  Recombinant ApoE4 for Dyslipidemia Drug Profile321
  Small Molecules to Activate ApoE for Alzheimer's Disease Drug Profile331
Apolipoprotein E (ApoE) Featured News &Press Releases3410
  Oct 14, 2015: Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides341
  Jul 23, 2015: Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides351
  Dec 16, 2014: Capstone Therapeutics Announces Phase 1b/2a Study Results for AEM-28 Showing Safety and Biomarker Efficacy Signals361
  Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals371
  Jun 11, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1b/2a Human Clinical Trial in Refractory Hypercholesterolemic Subjects381
  Jun 05, 2014: ApoE Immunotherapy and Prions Advance in Alzheimer s Research381
  Apr 08, 2014: Capstone Therapeutics Announces Initiation of Dosing for AEM-28 Phase 1 Human Clinical Trial in LDL/non-HDL Cholesterol Reduction391
  Nov 19, 2013: Capstone Therapeutics Announces a LipimetiX Development Presentation at the American Heart Association Scientific Sessions: Pre-Clinical Data Demonstrating Significant Post Treatment Benefit of AEM-28 on Established Atherosclerotic Lesions391
  Apr 24, 2013: ADDF And BrightFocus Foundation Collaborate To Fund Phase I Study Of Cancer Drug Bexarotene In Alzheimer's Disease Patients401
  Dec 06, 2012: Capstone Therapeutics's Partner LipimetiX Obtains Orphan Drug Designation For AEM-28 To Treat Homozygous Familial Hypercholesterolemia411
  Feb 09, 2012: Case Western Reserve Researchers Discover FDA-approved Drug Rapidly Clears Amyloid From Brain And Reverses Cognitive Defects413
Appendix442
  Methodology441
  Coverage441
  Secondary Research441
  Primary Research441
  Expert Panel Validation441
  Contact Us441
  Disclaimer451

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Apolipoprotein E (ApoE) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Apolipoprotein-E-ApoE-Pipeline-Review-H1-2016-2088-15993>
  
APA:
Global Markets Direct - Market Research. (2016). Apolipoprotein E (ApoE) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Apolipoprotein-E-ApoE-Pipeline-Review-H1-2016-2088-15993>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.